NASDAQ:DNTH Dianthus Therapeutics (DNTH) Stock Price, News & Analysis $35.65 -0.35 (-0.97%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$35.66 +0.01 (+0.01%) As of 10/17/2025 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Dianthus Therapeutics Stock (NASDAQ:DNTH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Dianthus Therapeutics alerts:Sign Up Key Stats Today's Range$34.63▼$36.3350-Day Range$18.89▼$39.5552-Week Range$13.36▼$40.16Volume657,913 shsAverage Volume672,953 shsMarket Capitalization$1.15 billionP/E RatioN/ADividend YieldN/APrice Target$60.88Consensus RatingModerate Buy Company Overview Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York. Read More Dianthus Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreDNTH MarketRank™: Dianthus Therapeutics scored higher than 54% of companies evaluated by MarketBeat, and ranked 505th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingDianthus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 10 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialDianthus Therapeutics has a consensus price target of $60.88, representing about 70.8% upside from its current price of $35.65.Amount of Analyst CoverageDianthus Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Dianthus Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Dianthus Therapeutics are expected to decrease in the coming year, from ($2.61) to ($3.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dianthus Therapeutics is -10.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dianthus Therapeutics is -10.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDianthus Therapeutics has a P/B Ratio of 2.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Dianthus Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.08% of the float of Dianthus Therapeutics has been sold short.Short Interest Ratio / Days to CoverDianthus Therapeutics has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Dianthus Therapeutics has recently decreased by 3.12%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDianthus Therapeutics does not currently pay a dividend.Dividend GrowthDianthus Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted17.08% of the float of Dianthus Therapeutics has been sold short.Short Interest Ratio / Days to CoverDianthus Therapeutics has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Dianthus Therapeutics has recently decreased by 3.12%, indicating that investor sentiment is improving. News and Social Media2.6 / 5News Sentiment0.75 News SentimentDianthus Therapeutics has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Dianthus Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 8 people have searched for DNTH on MarketBeat in the last 30 days. This is a decrease of -27% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Dianthus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $700,000.00 in company stock.Percentage Held by InsidersOnly 8.15% of the stock of Dianthus Therapeutics is held by insiders.Percentage Held by Institutions47.53% of the stock of Dianthus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Dianthus Therapeutics' insider trading history. Receive DNTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dianthus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DNTH Stock News HeadlinesEvaluating Dianthus Therapeutics (DNTH) Valuation After New DNTH212 Licensing Deal and Pipeline ExpansionOctober 16 at 12:40 AM | finance.yahoo.comDianthus Therapeutics Signs License Agreement with Nanjing LeadsOctober 16 at 2:39 PM | msn.comShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the rights to deliver direct-to-cell service nationwide — a move tech analyst Jeff Brown says could shape the backbone of the coming space economy and create fortunes on a scale not seen since the rise of NVIDIA.October 19 at 2:00 AM | Brownstone Research (Ad)Dianthus to license autoimmune disease candidate in a deal worth up $1BOctober 16 at 2:39 PM | msn.comDianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL ...October 16 at 9:37 AM | finance.yahoo.comDianthus Therapeutics Initiates Licensing Agreement for DNTH212, a Promising Treatment for Autoimmune Diseases with Unique Mechanism of ActionOctober 16 at 7:30 AM | quiverquant.comQDianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune DiseasesOctober 16 at 7:00 AM | globenewswire.comTruist Securities Initiates Coverage of Dianthus Therapeutics (DNTH) with Buy RecommendationOctober 15, 2025 | msn.comSee More Headlines DNTH Stock Analysis - Frequently Asked Questions How have DNTH shares performed this year? Dianthus Therapeutics' stock was trading at $21.80 at the start of the year. Since then, DNTH stock has increased by 63.5% and is now trading at $35.65. How were Dianthus Therapeutics' earnings last quarter? Dianthus Therapeutics, Inc. (NASDAQ:DNTH) issued its quarterly earnings data on Thursday, August, 7th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.86) by $0.02. The business had revenue of $0.19 million for the quarter, compared to analysts' expectations of $0.87 million. Dianthus Therapeutics had a negative trailing twelve-month return on equity of 34.72% and a negative net margin of 2,364.56%. Who are Dianthus Therapeutics' major shareholders? Dianthus Therapeutics' top institutional investors include Ethic Inc. (0.02%). Insiders that own company stock include Fairmount Funds Management Llc, Simrat Randhawa and Ryan Savitz. View institutional ownership trends. How do I buy shares of Dianthus Therapeutics? Shares of DNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Dianthus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dianthus Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and Invesco QQQ (QQQ). Company Calendar Last Earnings8/07/2025Today10/19/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DNTH CIK1690585 Webdianthustx.com Phone857-242-0170FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Price Target for Dianthus Therapeutics$60.88 High Price Target$100.00 Low Price Target$40.00 Potential Upside/Downside+70.8%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($3.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$84.97 million Net Margins-2,364.56% Pretax Margin-2,364.60% Return on Equity-34.72% Return on Assets-32.72% Debt Debt-to-Equity RatioN/A Current Ratio13.12 Quick Ratio13.12 Sales & Book Value Annual Sales$4.85 million Price / Sales236.40 Cash FlowN/A Price / Cash FlowN/A Book Value$11.91 per share Price / Book2.99Miscellaneous Outstanding Shares32,188,000Free Float29,565,000Market Cap$1.15 billion OptionableOptionable Beta1.58 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:DNTH) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.